[A21-160] Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 19.04.2022
Project no.:
A21-160
Commission:
Commission awarded on 08.12.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with treatment-naive advanced renal cell carcinoma
Result of dossier assessment:
- Favourable risk profile (IMDC score 0): added benefit not proven
- Intermediate (IMDC score 1-2) or unfavourable risk profile (IMDC score ≥ 3): added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-122 | Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-19 | Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-57 | Lenvatinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-63 | Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G15-06 | Lenvatinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| A21-162 | Lenvatinib (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |